Alnylam Pharmaceuticals and a few other drug firms are rekindling interest in once-hot gene technology, which seeks to disable molecules called RNA from translating genetic code into disease-causing proteins.
from WSJ.com: US Business http://ift.tt/1juJKND
via IFTTT
from WSJ.com: US Business http://ift.tt/1juJKND
via IFTTT
No comments:
Post a Comment